PMID- 18678970
OWN - NLM
STAT- MEDLINE
DCOM- 20081028
LR  - 20191111
IS  - 0389-5386 (Print)
IS  - 0389-5386 (Linking)
VI  - 52
IP  - 3
DP  - 2008 Jul
TI  - Co-treatment with basic fibroblast growth factor and 17beta-estradiol in the 
      presence of dexamethasone accelerates bone formation by rat bone marrow stromal 
      cell culture.
PG  - 366-74
AB  - PURPOSE: Bone marrow stromal cells (BMSCs) are a promising cell source in 
      applications for tissue engineering and regenerative medicine. Optimization and 
      control of the growth and differentiation of cultivated cells can be achieved by 
      the administration of growth factors and hormones in vitro. This study provided 
      experimental information on the enhancement of the osteogenic potential of rat 
      BMSCs in vitro and in vivo. METHODS: Mineralized nodule formation of rat BMSCs in 
      culture for 3 weeks with dexamethasone (Dex)-treated media supplemented with both 
      basic fibroblast growth factor (bFGF) and 17beta -estradiol (E2) was examined by 
      histology. In porous beta-tricalcium phosphate (beta - TCP), proliferation, 
      migration, and differentiation of BMSCs were examined by histology and 
      transmission electron microscopy. After culturing, the composites were 
      subcutaneously implanted into syngeneic rats. The tissues with implants were 
      harvested after 4 weeks and evaluated microscopically by using histological 
      stain. RESULTS: Dex-treated media supplemented with both bFGF and E2 was the most 
      effective in mineralized nodule formation of BMSCs in vitro. Light and electron 
      microscopy revealed the presence of many cells with developed rough endoplasmic 
      reticulum. Bone formation in the BMSC/beta -TCP composites in cultures in vitro 
      for 3 weeks was observed histologically at 4 weeks after implantation. When 
      BMSC/beta -TCP composites were cultured in Dex-treated media supplemented with 
      both bFGF and E2, the amount of bone formation at implants was substantially 
      greater than that of composites cultured in Dex-treated media supplemented with 
      bFGF. CONCLUSION: The combined use of bFGF and E2 could effectively improve the 
      bone-forming ability of BMSCs.
FAU - Ozono, Satoru
AU  - Ozono S
AD  - Institute for Frontier Oral Science, Kanagawa Dental College, Yokosuka, Kanagawa, 
      Japan. ozonostr@kdcnet.ac.jp
FAU - Fujita, Tadahiro
AU  - Fujita T
FAU - Matsuo, Masato
AU  - Matsuo M
FAU - Todoki, Kazuo
AU  - Todoki K
FAU - Ohtomo, Takatsune
AU  - Ohtomo T
FAU - Negishi, Hideyuki
AU  - Negishi H
FAU - Kawase, Toshio
AU  - Kawase T
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Nihon Hotetsu Shika Gakkai Zasshi
JT  - Nihon Hotetsu Shika Gakkai zasshi
JID - 7505724
RN  - 0 (Calcium Phosphates)
RN  - 0 (beta-tricalcium phosphate)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 4TI98Z838E (Estradiol)
RN  - 7S5I7G3JQL (Dexamethasone)
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells/*physiology
MH  - Calcium Phosphates
MH  - Cells, Cultured
MH  - Dexamethasone/*pharmacology
MH  - Drug Synergism
MH  - Estradiol/*pharmacology
MH  - Fibroblast Growth Factor 2/*pharmacology
MH  - Male
MH  - Osteogenesis/*drug effects
MH  - Rats
MH  - Rats, Inbred F344
MH  - Stimulation, Chemical
MH  - Stromal Cells/*physiology/transplantation
EDAT- 2008/08/06 09:00
MHDA- 2008/10/29 09:00
CRDT- 2008/08/06 09:00
PHST- 2008/08/06 09:00 [pubmed]
PHST- 2008/10/29 09:00 [medline]
PHST- 2008/08/06 09:00 [entrez]
AID - 10.2186/jjps.52.366 [doi]
PST - ppublish
SO  - Nihon Hotetsu Shika Gakkai Zasshi. 2008 Jul;52(3):366-74. doi: 
      10.2186/jjps.52.366.